Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Morphea
NCT03679845Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sarilumab in morphea, sponsored by Massachusetts General Hospital. Planned start Sep 2019; status: withdrawn.
02
Drugs
sarilumab
03
Conditions
morphea
Beyond the preview
Go deeper on NCT03679845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679845.